中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 36 Issue 4
Apr.  2020
Turn off MathJax
Article Contents

Effect of fenofibrate on the diversity of intestinal flora in a mouse model of nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2020.04.024
Research funding:

 

  • Received Date: 2019-11-17
  • Published Date: 2020-04-20
  • Objective To investigate the effect of fenofibrate on the diversity of intestinal flora in mice with nonalcoholic fatty liver disease( NAFLD). Methods A total of 30 mice were randomly divided into normal group,high-fat group,and fenofibrate treatment group,with10 mice in each group. The mice in the high-fat group and the fenofibrate treatment group were given high-fat diet intervention for 14 weeks,and those in the normal group were given normal diet for 14 weeks. After 10 weeks of dietary intervention,the mice in the fenofibrate treatment group were given fenofibrate by gavage and high-fat diet for another 4 weeks,and the change in body weight was monitored during the whole process. Fecal samples were collected after 14 weeks,and high-throughput sequencing 16 S rRNA was used to investigate the diversity and difference of intestinal flora. Liver tissue samples were collected,and HE staining and oil red O staining were performed to observe the degree of steatosis. A one-way analysis of variance was used for comparison between multiple groups,and the least significant difference t-test was used for further comparison between two groups. Results After 10 weeks of intervention,the fenofibrate treatment group had a significantly lower body weight than the high-fat group( P < 0. 05). The results of HE staining and oil red O staining showed that the fenofibrate treatment group had a significantly lower degree of fat deposition than the high-fat group. There was a significant difference in intestinal flora between the fenofibrate treatment group and the high-fat group,while there was no significant difference in intestinal flora between the fenofibrate treatment group and the normal group. The fenofibrate treatment group had significant increases in the abundance of Bacteroidetes,Verrucomicrobia,Faecalibaculum,Muribaculaceae_norank,and Akkermansia and significant reductions in the abundance of Firmicutes,Actinobacteria,Clostridium,Turicibacter,and Bifidobacterium. Conclusion The increases in the abundance of Bacteroidetes and Verrucomicrobia and the reductions in the abundance of Firmicutes and Actinobacteria suggest that fenofibrate may have positive significance in the treatment of NAFLD.

     

  • loading
  • [1] JIANG YZ,NIE HM,WANG R. Research advances in the pathogenesis of nonalcoholic fatty liver disease[J]. J Clin Hepatol,2019,35(11):2588-2591.(in Chinese)姜煜资,聂红明,汪蓉.非酒精性脂肪性肝病的发病机制[J].临床肝胆病杂志,2019,35(11):2588-2591.
    [2] FRIEDMAN SL,NEUSCHWANDER BA,MARY R,et al. Mechanisms of NAFLD development and therapeutic strategies[J].Nat Med,2018,24(7):908-922.
    [3] PIMPIN L,CORTEZ-PINTO H,NEGRO F,et al. Burden of liver disease in Europe:Epidemiology and analysis of risk factors to identify prevention policies[J]. J Hepatol,2018,69(3):718-738.
    [4] ARAU'JO AR,ROSSO N,BEDOGNI G,et al. Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis:What we need in the future[J]. Liver Int,2018,38(Suppl 1):47-51.
    [5] CORTE CD,MAZZOTTA AR,NOBILI V. Fatty liver disease and obesity in youth[J]. Curr Opin Endocrinol Diabetes Obes,2016,23(1):66-71.
    [6] GUREEV AP,SHMATKOVA ML,BASHMAKOV VY,et al. The effect of fenofibrate on expression of genes involved in fatty acids beta-oxidation and associated free-radical processes[J]. Biomed Khim,2016,10(1):70-74.
    [7] LEFEBVRE P. Sorting out the roles of PPARαin energy metabolism and vascular homeostasis[J]. J Clin Invest,2006,116(3):571-580.
    [8] HUANG FF,WANG JJ,YU FM,et al. Protective effect of meretrix meretrix oligopeptides on high-fat-diet-induced nonalcoholic fatty liver disease in mice[J]. Mar Drugs,2018,16(2):39-55.
    [9] ZHANG D,MA LQ. Research advances in the role and mechanism of peroxisome proliferator-activated receptor alpha in liver diseases[J]. J Clin Hepatol,2019,35(10):2351-2354.(in Chinese)张丹,马岚青.过氧化物酶体增殖激活受体α在肝脏疾病中的作用及机制[J].临床肝胆病杂志,2019,35(10):2351-2354.
    [10] MONTAGNER A,POLIZZI A,FOUCHE E,et al. Original article:Liver PPARαis crucial for whole-body fatty acid homeostasis and is protective against NAFLD[J]. Gut,2016,65(7):1202-1214.
    [11] YAO FF,JIA RP,HUANG H,et al. Effect of Lactobacillus paracasei N1115 and fructooligosaccharides in nonalcoholic fatty liver disease[J]. Arch Med Sci,2019,15(5):1336-1334.
    [12] LU S,ZHANG T,GU W,et al. Volatile oil of amomum villosum inhibits nonalcoholic fatty liver disease via the gut-liver axis[J]. Bio Med Res Int,2018,7(19):35-48.
    [13] LI F,SUN G,WANG ZK,et al. Characteristics of fecal microbiota in non-alcoholic fatty liver disease patients[J]. Sci China Life Sci,2018,61(7):770-778.
    [14] QUAN M,XING HC. Research progress on intestinal flora and chronic liver diseases[J/CD]. Chin J Liver Dis(Electronic Version),2019,11(3):26-30.(in Chinese)全敏,邢卉春.肠道菌群与慢性肝病相关研究进展[J/CD].中国肝脏病杂志(电子版),2019,11(3):26-30.
    [15] MA JL,ZHOU QH,LI HK. Gut microbiota and nonalcoholic fatty liver disease:Insights on mechanisms and therapy[J].Nutrients,2017,9(10):e1124.
    [16] YU X,WANG WJ,JIN JY,et al. Linggui Zhugan decoction combined with probiotics in the treatment of nonalcoholic fatty liver disease[J]. J Changchun Univ Chin Med,2019,35(5):891-894.(in Chinese)喻晓,王雯婕,金嘉悦,等.苓桂术甘汤联合益生菌治疗非酒精性脂肪肝[J].长春中医药大学学报,2019,35(5):891-894.
    [17] LIU HL,LIU MH,FU XQ,et al. Astaxanthin prevents alcoholic fatty liver disease by modulating mouse gut microbiota[J].Nutrients,2018,10(9):1298-1315.
    [18] YOUNGMI J,INYOUNG K,MOHAMED M,et al. Effect of Kombucha on gut-microbiota in mouse having non-alcoholic fatty liver disease[J]. Food Sci Biotechnol,2018,28(1):261-267.
    [19] GUO J,CHEN YY,YE F. Therapeutic efects of fenofibrate on nonalcoholic faty liver disease in vitro and related mechanism[J]. Acta Med Univ Sci Technol Huazhong,2017,46(3):265-270.(in Chinese)郭骏,陈玉媛,叶枫.非诺贝特缓解非酒精性脂肪性肝病的体外机制研究[J].华中科技大学学报:医学版,2017,46(3):265-270.
    [20] ZHANG N,LU Y,SHEN X,et al. Fenofibrate treatment attenuated chronic endoplasmic reticulum stress in the liver of nonalcoholic fatty liver disease mice[J]. Pharmacology,2015,95(3-4):173-180.
    [21] HOJYO S,FUKADA T. Zinc transporters and signaling in physiology and pathogenesis[J]. Arch Biochem Biophys,2016,611:43-50.
    [22] NAN J,YANG SX. Research advances in non-statin drugs for lipid regulation[J]. Chin J Geriatr Heart Brain Vess Dis,2016,18(6):655-658.(in Chinese)南京,杨水祥.非他汀类调脂药物的研究进展[J].中华老年心脑血管病杂志,2016,18(6):655-658.
    [23] SUK KT,KIM DJ. Gut microbiota:Novel therapeutic target for nonalcoholic fatty liver disease[J]. Expert Rev Gastroenterol Hepatol,2019,13(3):193-204.
    [24] LIU CC,LI W,WANG LY. Relationship between gut microbiota and non-alcoholic fatty liver disease[J]. Chin J Gastroenterol Hepatol,2017,26(10):1103-1106.(in Chinese)刘晨晨,李稳,王凌云.肠道菌群与非酒精性脂肪性肝病关系的研究进展[J].胃肠病学和肝病学杂志,2017,26(10):1103-1106.
    [25] LU M,TANG YC,LI M,et al. Co-administration of cholesterol-lowering probiotics and anthraquinone from cassia obtusifolia l. ameliorate non-alcoholic fatty liver[J]. PLo S One,2015,10(9):e0138078.
    [26] LIU BH,ZHANG J,SUN P,et al. Raw bowl tea(tuocha)polyphenol prevention of nonalcoholic fatty liver disease by regulating intestinal function in mice[J]. Biomolecules,2019,9(435):1-20.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1270) PDF downloads(221) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return